IDEAYA BIOSCIENCES AND SERVIER ANNOUNCE DATA FROM THREE CLINICAL TRIALS AT ESMO 2026 SUPPORTING THE POTENTIAL OF DAROVASERTIB TO BECOME A FOUNDATIONAL NEW THERAPY FOR PATIENTS ACROSS THE TREATMENT JOURNEY OF UVEAL MELANOMA

Reuters · 2d ago

Please log in to view news